Both genetic and environmental factors have been considered causative agents for schizophrenia (SZ). However, no single gene has been shown responsible for the development of SZ. Furthermore, the pathophysiological roles of environmental factors including psychological stress, autoimmunity, and microbial infection have not been fully understood. Previous studies have suggested the involvement of one of the human endogenous retroviruses (HERVs), HERV-W, in SZ. In this study, prevalence of antibodies against the HERV-W Syncytin-1 protein was examined using a newly developed ELISA test. Fifty percent of patients with SZ (24 out of 48 cases) were antibody-positive, with a specificity of greater than 95% (less than 5% of control cases, 3 out of 79). No significant effect of medication was evident, nor did any SZ cases become seropositive after diagnosis. These findings indicate a possible involvement of HERV-W expression in the development of SZ and support its applicability to laboratory diagnoses.
Introduction
Schizophrenia (SZ) is a major psychiatric disorder that affects 0.5 to 1.0% of the populations in most countries, irrespective of socio-economic conditions (Owen et al, 2016) . Diagnosis of SZ is often made by experienced psychiatric experts in accordance with the Diagnostic and Statistical Manual of Mental Disorders, 5 th edition (DSM-5) (American Psychiatric Association, 2013) or the International Classification of Diseases, 10 th edition (ICD-10) (WHO, 1992) ; neither includes objective diagnostic measures, such as laboratory tests. In addition, differential diagnosis of closely related psychiatric conditions such as bipolar disorder (BD) and schizoaffective disorder is not currently clear. Thus, non-invasive blood testing is needed to facilitate early and objective diagnosis of psychopathic patients.
Although a number of genome-wide association studies (GWASs) have demonstrated a genetic predisposition to SZ (Lichtenstein et al, 2009; Purcell et al, 2014; Takata et al, 2017) , no single gene has been shown to be responsible. Other studies have revealed complex interactions between the nervous and immune-inflammatory systems (Khandaker et al, 2015; Fillman et al, 2013) . Interestingly, a recent epidemiological study confirmed a link between SZ and autoimmunity (Heath et al, 1967; Chen et al, 2012; Benros et al, 2014; Cremaschi et al, 2017) . For instance, a nationwide risk-assessment study revealed a cross relationship between these two pathologies (Benros et al, 2014; Cremaschi et al, 2017) with an increased risk of subsequent autoimmune diseases in individuals with SZ. In addition, subsequent studies indicated a overlap in common SNPs between schizophrenia and autoimmune diseases (Hoeffding et al, 2017) . These findings suggest the presence of a common etiological mechanism.
The human genome contains a number of retrovirus-related sequences, including human endogenous retroviruses (HERV), long interspersed nuclear elements (LINE) and short interspersed nuclear elements (SINE) , that comprise nearly 45% of the entire genome (Kazazia et al, 2017) . Most of these sequences are considered to have been derived from previously infected ecotropic retroviruses even before the divergence of Homo sapiens from the rest of the mammals. Conservation of these sequences over time may be indicative of their pivotal roles in cell differentiation or immunological and neuronal diversification (Kazazia et al, 2017) . HERV sequences generally degenerate and lose open reading frames throughout molecular evolution (Kazazia et al, 2017) .
However, one such HERV, HERV-W, contains a conserved long open reading frame of 538 amino acids (AAs), named Syncytin-1 (Mi et al, 2000; Lavialle et al, 2013) . The expression of syncytin-1 is considered essential for placenta organogenesis as its expression has been demonstrated to induce the syncytiotrophoblast (Mi et al, 2000; Lavialle et al, 2013) and is tightly regulated by an epigenetic mechanism (Matousková et al, 2016) . Gene expression of HERV-W is aberrantly induced under extreme conditions such as viral infection and carcinogenesis (Kassiotis, 2014; , playing as a molecular marker for the cell damage and its transformation.
Thus, presence of HERV is considered beneficial for the maintenance of species.
HERV-W was first isolated from the cerebrospinal fluid of patients with multiple sclerosis and was thus initially named the multiple sclerosis-associated retrovirus (MSRV) (Kurth, 1986) . It is possible aberrant expression of HERV-W might trigger the aberrant immune responses followed by chronic inflammation and the neurodegenerative changes characteristic for multiple sclerosis (MS). Furthermore, HERV-W is considered to be involved in a number of other diseases. Interestingly, expression of the HERV-W sequence has been previously observed in the brain tissue of SZ patients as well as healthy brain tissues (Yolken et al, 2000; Karlsson et al, 2001; Frank et al, 2005) . In addition, expression of HERV-W sequences were detected in the cerebrospinal fluid of SZ patients (Frank et al, 2005) . More specifically, the Syncytin-1 protein and its mRNA were detected in the sera of SZ patients (Perron et al, 2008; Perron et al, 2012) . However, no evidence for the presence of the anti-Syncytin-1 antibody in these patients has yet to be demonstrated. In this study, we demonstrate for the first time that antibodies against the Syncytin-1 protein are present in the blood of individuals with psychiatric diseases.
Implication of the presence of Syncytin-1 autoantibody will be discussed.
Results
We have examined the prevalence of anti-Syncytin-1 antibody among neuropsychiatric patients including SZ
[n=48], bipolar disorder (BD) [n=18], MS [n=17] and control subjects [n=79] . There were no significant differences in the male to female ratio or average age among different disease categories (Table 1 ). The anti-Syncytin-1 antibody was also examined in BD known crossly related to SZ (Owen et al, 2016; American Psychiatric Association, 2013; WHO, 1992) . To initially screen the anti-Syncytin-1 antibody, we applied Western blotting using semi-purified recombinant full-length Syncytin-1 protein (Appendix Fig. S1 ). However, because of the instability of semi-purified proteins due to high hydrophobicity upon Western blotting (e.g., the broadening of the immune-reacted bands) as well as the technical difficulty in purifying the protein, we attempted to develop a novel antibody screening method using ELISA and antigenic peptides derived from Syncytin-1.
In order to develop a specific ELISA system for anti-Syncytin-1 antibody detection, we determined commonly-recognized Syncytin-1 epitopes using a Syncytin-1 peptide array (Fig. 1) . The results indicated that most of the positive sera reacted to the peptides containing various epitope regions (Fig. 1a) . The shaded areas in Fig. 1B indicated the Syncytin-1 peptide regions that were highly immune-reactive to each patient's serum (quantitation of the spots demonstrated in Fig. 1a ). Each peptide sequence is listed in Appendix Table S2 . Among the 48 SZ patients there was no significant difference in the presence of pathognomonic symptoms such as hallucinations, delusions, thought disorders, movement disorders, "flat affect" or reduced speaking, irrespective of the presence of anti-Syncytin-1 antibody (Table 1) .
Based on these serological findings, we have determined the antigenic peptide for ELISA screen (Fig. 2) .
Among the eight peptides of Syncytin-1, only the peptide #8 exhibited anti-Syncytin-1 antigenicity, and the inclusion of other peptides unexpectedly exhibited interfering effects (Fig. 2b) . The peptide competition experiments in Fig. 2c show that the immune-reactivity of most positive sera against Syncytin-1 peptide #8 was inhibited only by the homologous peptide and not by the other peptides. We do not currently know the reason for the preferred antigenicity in peptide #8. However, since this peptide region is located in the cytoplasm (Mi et al, 2000; Lavialle et al, 2013) and is unlikely to be exposed, the antibody response could not have been elicited unless cells were destroyed to expose the membrane protein fractions including Syncytin-1. Fig. 3a demonstrates the results of anti-Syncytin-1 antibody using ELISA system with sera from SZ, BD, MS, and controls. The antibody cut-off value was determined by the ROC curve ( Fig. 3b ). As summarized in Table 1 (bottom line), the anti-Syncytin-1 seroprevalence in SZ, BD and MS was 50.0% (24/48), 22.3% (4/18) and 17.6%
(3/17), respectively; whereas that in controls was 3.8%. All positive sera against Syncytin-1 in Western blotting were also positive in ELISA. Some samples exhibiting the negative result in Western blotting showed positive reactivity in ELISA, indicating the higher sensitivity for ELISA. We thus used the ELISA system to examine the anti-Syncytin-1 antibody in 9 schizophrenic patients over time and found that the anti-Syncytin-1 antibody reactivity was largely stable except for a few cases, in which the immunoreactivity varied slightly in accordance with physical or mental stress (Fig. 4) . Since HDAC inhibitors, such as valproic acid (VPA), are known to inhibit the maintenance of histone deacetylation and could possibly induce expression of repressed genes such as HERVs (Matousková et al, 2016; Diem et al, 2012) , we have assessed the effects of VPA administration on the anti-Syncytin-1 antibody in SZ patients. However, there was no significant difference in antibody prevalence, irrespective of the VPA treatment of psychiatric patients. There was no subject who exhibited seropositivity in 9 patients under the VPA treatment to prevent seizures after brain surgery (data not shown).
Discussion
Although SZ affects a large proportion of the general population throughout the world, its diagnosis has usually been made only by psychiatric experts, and most patients do not initially have direct access to medical care (Owen et al, 2016) . Thus, novel diagnostic measures are needed to detect SZ upon initial manifestation of symptoms for further medical care of such patients. Our present findings of anti-Syncytin-1 antibody detection in psychiatric patients would meet such a need. Further verifications with extended study subjects should verify the significance of anti-Syncytin-1 antibody detection. These include determining whether this antibody is (i)
produced as a result of various therapeutic measures or medical interactions that could modify the antibody production, (ii) detected in younger SZ patients upon its initial diagnosis, (iii) detected in other conditions related to SZ such as BD and schizoaffective disorders, (iv) produced as cause/effect of such pathologic conditions or (v) detected in SZ patients in other countries. As far as this initial study is concerned, there was no psychiatric case in which the antibody was detected after the diagnosis of SZ or BD was made. We observed subtle fluctuations of the antibody titer during the disease course (Fig. 4) , which needs to be further verified. Regarding the influence of epigenetic modifiers such as VPA for expression of HERV-W (Diem et al, 2012) and production of anti-Syncytin-1 antibody, we did not observe a significant correlation between the use of VPA and the prevalence of anti-Syncytin-1 antibody (data not shown).
Previous reports suggested a possible relationship between autoimmunity and SZ (Heath et al, 1967; Chen et al, 2012) . In addition to the recent epidemiological studies (Benros et al, 2014; Cremaschi et al, 2017) , a number of studies reported the presence of autoantibodies such as antinuclear antibodies and anti-N-methyl-D-aspartic acid receptor (NMDAR) antibodies in SZ patients (van Mierlo et al, 2015; Kristiansen et al, 2007; Coyle, 2006) .
On the other hand, patients with paraneoplastic syndrome associated with ovarian teratome exhibiting anti-NMDAR autoantibodies often manifest SZ-like symptoms such as hallucinations, delusions and thought disorders (Vitaliani et al, 2005) . Moreover, the presence of neuro-reactive antibodies have been demonstrated in various diseases involving the neuromuscular system such as systemic lupus erythematousus (SLE) (Hanly et al, 1994) , Guillain-Barre syndrome (Yuki et al, 2012) and myasthenia gravis (Patrick et al, 1973) . The presence of anti-Syncytin-1 antibody in SZ patients suggests the involvement of autoimmune mechanism in its pathogenesis as well. However, although expression of HERV-W has been previously demonstrated, there is no significant difference in the extent of its expression among SZ, BD and healthy subjects (Karlsson et al, 2001) . Moreover, the presence of anti-Syncytin-1 antibody does not necessarily satisfy the classical and the revised postulates defining the autoimmunity (Rose et al, 1993) . It is also noted that various factors known to induce HERV-W expression, such as infection with influenza and herpes viruses, are also recognized as risk factors for SZ (Li et al, 2014; . These findings collectively suggest the link between SZ and autoimmunity although its role in SZ pathogenesis is not as straightforward as in other autoimmune diseases such as SLE.
Our present findings suggest the involvement of retrotransposons such as HERV-W in the pathophysiology of SZ (Karlsson et al, 2001; Perron et al, 2008; Perron et al, 2012) . Previous reports demonstrated the expression of HERV sequences in brain (Yolken et al, 2000; Karlsson et al, 2001; Frank et al, 2005) and sequencing of the chromosome rearrangement site at the chromosomal break point revealed the involvement of HERVs (Feschotte et al, 2012; Weckselblatt et al¸ 2015; Lee et al, 2015) . Moreover, Ohnuki et al. reported the involvement of HERV-H activation in the differentiation from inducible multipotent stem (iPS) cells (Ohnuki et al, 2014) . These findings suggest that the genetic rearrangement involves retrotransposons such as LINE and HERVs (Muotri et al, 2005;  1 0 Evrony et al, 2012; Upton et al, 2015; Erwin et al, 2016) . It is possible that aberrant or excessive activation of retrotransposons in neuronal cells and elicitation of host immune responses might be associated with neuropsychiatric disorders such as SZ. Gage et al. further postulated the active role of genetic mosaicism generated by such retrotransposons on the proper differentiation of neurons and construction of neuronal networks (Muotri et al, 2005; Erwin et al, 2016) . A number of subsequent studies utilized a single cell genome sequencing technique and have revealed that up to 60% (Erwin et al, 2016) , though still controversial (Evrony et al, 2016) , of neuronal cells in healthy individuals undergo genetic rearrangement (Muotri et al, 2005; Evrony et al, 2012; Upton et al, 2015; Erwin et al, 2016) . It is possible that the neuronal connectivity for the construction and maintenance of basic cognitive brain functions might have been impaired in SZ and BD brains. Interestingly, Bundo et al. reported that the frequency of L1 retrotransposition is higher in the prefrontal cortex of the post-mortem brains of SZ patients and that the L1-insertion was preferentially localized to synapse-and SZ-related genes (Bundo et al, 2014) .
The activation of retrotransposons, including HERVs as well as LINE, might disorganize the directed genomic rearrangement of neuronal cells. This aberrant neuronal genetic rearrangement might deceive the decent formation of neuronal circuits by interfering with physiological synaptic connectivity, eventually leading to the development of neuropsychiatric disorders. Further molecular analyses are needed to clarify the relationship between the emergence of the anti-Syncytin-1 antibody and disease occurrence. Such studies should provide a novel approach for diagnosis and understanding of the pathogenesis of psychiatric diseases and could facilitate development of specific therapies involving the control of excessive retrotransposition using retroviral reverse transcriptase or integrase inhibitors. 1
Materials and Methods

Sera from patients and controls.
Sera from patients with schizophrenia (SZ; 48 cases) and bipolar disorder (BD; 18 cases) were collected from hospitalized patients in Yahagigawa Hospital. Informed consent was obtained from each patient or their family after a thorough explanation of the purpose of the study. Sera from patients with multiple sclerosis (MS; 17 cases) and the control group (Cont; 79 cases) were similarly collected from Nagoya City University Hospital, Fuji
Hospital and Tomita Hospital. Sera from patients under treatment with valproic acid (VPA; 7 cases) were collected after brain surgery in the Fuji Hospital. These sera were kept at 4 °C or frozen until use. Diagnoses of SZ and BD were made after the agreement of at least 2 psychiatric specialists using international criteria for disease classification, such as the DSM-5 (American Psychiatric Association, 2013) and ICD-10 (WHO, 1992) . Patients with autoimmune diseases, cancer, conventional viral infections, or other psychiatric conditions were excluded from the study. This study was approved by the Medical Ethics Committee of each institution involved in the study (Approved number from Nagoya City University: No. 60-00-0886) and was conducted in accordance with the principles of the Helsinki Declaration.
Synthetic DNA oligonucleotide and plasmids.
The entire syncytin-1 coding region of HERV-W (Mi et al, 2000; Lavialle et al, 2013) and the codon-substituted versions were synthesized enzymatically based on the nucleotide sequence, using the primers shown in Appendix   Table S1 . Institutes of Health, USA). The relative intensity (%) of each spot was calculated using the sum of all spot intensities in each peptide microarray.
Synthetic peptides for ELISA
The peptides used for ELISA were synthesized through a conventional method in Optimal Biotech Pte Ltd, Singapore. Their purity was assessed using high-performance liquid chromatography and mass spectrometry.
Details of these synthetic peptides are described in Appendix Table S2 .
ELISA
To quantitatively determine the immunoreactivity of each serum sample, an Immobilizer TM Amino (Nunc) plate was coated with Syncytin-1 peptide #8 at 10 μg/mL in 100 mM sodium carbonate buffer [pH 9.6] at 25 °C for 2 h.
Nonspecific binding sites were blocked by the blocking buffer (100 mM sodium carbonate buffer [pH 9.6], 10 mM ethanolamine-HCl) at 25 °C for 2 h. After washing, a 1:100 dilution of the patient's serum in dilution buffer (1x PBS, 0.05% Tween-20, 0.1% NP-40, 3% skim milk) was incubated overnight at 4 °C. After washing, the sample was incubated with an HRP-conjugated secondary antibody against human IgG (GE Healthcare) (1:4,000 diluted) for 2 h at 25 °C. Subsequently, 100 μL of substrate buffer (0.1 mg/mL 3,3',5,5'-Tetramethylbenzidine
[TMB] substrate, 50 mM phosphate-citrate buffer [pH 5.0], 0.006% hydrogen peroxide) was added, and the plate was incubated at room temperature for 30 min in the dark, and the reaction was terminated using a stop buffer (1 M HCl). Absorbance was measured at 450 nm (reference 690 nm) using a Tecan Sunrise TM plate reader. In order to assure consistent washing, each wash was performed using 300 μl of wash buffer (1x PBS, 0.05% Tween-20, 0.1% NP-40). Five such washes were performed using a commercial plate washer (AMW-8; BioTec, Japan).
Competitive ELISA
Competitive ELISA was carried out in order to confirm the specificity of the antibody epitope. Each serum (at 1:100 dilution) was incubated with 0.001-10 μg/mL concentrations of the competitor peptide for 2 h at 25 °C. The reaction was performed in the same manner as that of a standard ELISA assay. Subsequently, the sample was subjected to the same ELISA protocol.
Statistical analysis
All statistical analyses were performed using R software version 3.3.2 (Stanford University Social Science Data and Software, Stanford, USA). The significance of the difference in the male to female ratio was analyzed using a χ1 6 both cases. The distribution of antibody titers detected by ELISA was analyzed using Wilcoxon's rank sum test. A p-value of less than 0.05 was considered statistically significant, and all reported p-values were two-tailed.
Receiver Operating Characteristic (ROC) curves were generated using the R statistical package and ROCR.
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RESULT:
In this study, we have attempted to establish a novel diagnostic ELISA system for schizophrenia by examining the serum antibodies against Syncytin-1 protein encoded by HERV-W. We have identified the immune-reactive epitope against Syncytin-1 and established a simple and reproducible ELISA antibody screening assay system using the immune-dominant epitope peptide. Using this ELISA system, nearly 50% of patients with schizophrenia (24 out of 48 cases) exhibited seropositivity to Syncytin-1 whereas less than 4% exhibited positive in the control subjects (sensitivity 50.0%; specificity 96.2%). ELISA. In order to assess the specificity of anti-Syncytin-1 ELISA detection system using Syncytin-1 peptide #8, two SZ sera (SZ-14 and SZ-16), one BD serum (BD-6), and a control serum (Cont-3) were examined. They were 7
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